11 hours ago
1
Lisa Maree Williams/Getty Images News
AstraZeneca (NASDAQ:AZN) plans to submit regulatory filings for its blood pressure treatment baxdrostat by the end of this year, seeking approval for the small molecule therapy potentially in 2026, Reuters reported on Saturday, citing a senior company executive.
"There's a
English (US) ·